All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus, affecting approximately 40% of the patients. Furthermore, around 44% of the patients with class IV LN develop end-stage kidney disease within 15 years. Notably, 13%–37% of patients undergoing standard therapy (ST) for LN experience renal flare within 3–5 years, emphasizing the need for novel treatments to preserve kidney function.
The phase III, randomized, double-blind BLISS-LN study (NCT01639339) has demonstrated that the addition of belimumab to ST improves renal outcomes in patients with active LN. However, data on its efficacy at different disease stages or with different induction regimens is limited. Here, we present a visual abstract summarizing post-hoc analyses from the BLISS-LN trial in patients with newly diagnosed or relapsed LN, including those with or without glucocorticoid pulses at induction.1
To download this visual abstract, click below.Download here
Management of systemic lupus erythematosus and lupus nephritis: Updated 2023 recommendations from EULAR
Here, we provide an overview of the updated European Alliance of Associations for Rheumatology (EULAR) treatment recommendations for extrarenal...
What do HCPs need to know about LN and the prevention of progression to ESRD?
The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to...
Subscribe to get the best content related to lupus delivered to your inbox